reports
Shijiazhuang Kelin Electric Co Ltd: 2 directors
Two Directors at Shijiazhuang Kelin Electric Co Ltd bought 307,700 shares at between 27.502CNY and 27.535CNY. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company...
Kendrion N.V.: 1 director
A director at Kendrion N.V. bought 7,600 shares at 13.300EUR and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Chocoladefabriken Lindt & Sprungli AG: 1 director
A director at Chocoladefabriken Lindt & Sprungli AG sold 240 shares at 10,603.000CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
EQS-News: Vossloh receives another major order to supply rail fastenin...
EQS-News: Vossloh Aktiengesellschaft / Key word(s): Incoming Orders Vossloh receives another major order to supply rail fastening systems in China 08.05.2024 / 13:30 CET/CEST The issuer is solely responsible for the content of this announcement. Vossloh receives another major order to supply rail fastening systems in China Systems serve the construction of two high-speed lines The order is valued at the equivalent of around €40 million Deliveries planned from 2025 Werdohl, May 8, 2024. Vossloh has once again been awarded a contract to supply rail fastening systems in ...
TKB-Geschäftsbericht 2023 verabschiedet
Thurgauer Kantonalbank / Schlagwort(e): Sonstiges TKB-Geschäftsbericht 2023 verabschiedet 08.05.2024 / 13:30 CET/CEST Medienmitteilung vom 8. Mai 2024 An seiner heutigen Sitzung hat der Thurgauer Grosse Rat den Geschäfts- und Nachhaltigkeitsbericht der Thurgauer Kantonalbank (TKB) genehmigt. Somit ist auch die Dividendenausschüttung für das Geschäftsjahr 2023 definitiv. Diese wurde auf 3,30 Franken pro Partizipationsschein erhöht. Der Thurgauer Grosse Rat hat an seiner Sitzung vom 8. Mai 2024 den Jahresbericht und die Jahresrechnung 2023 der TKB genehmigt. Die Revisionsstelle PWC w...
EQS-News: Vossloh erhält erneut Großauftrag zur Lieferung von Schienen...
EQS-News: Vossloh Aktiengesellschaft / Schlagwort(e): Auftragseingänge Vossloh erhält erneut Großauftrag zur Lieferung von Schienenbefestigungssystemen in China 08.05.2024 / 13:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Vossloh erhält erneut Großauftrag zur Lieferung von Schienenbefestigungssystemen in China Systeme dienen dem Bau von zwei Hochgeschwindigkeitsstrecken Auftragswert beträgt umgerechnet rund 40 Mio.€ Auslieferungen ab 2025 geplant Werdohl, 8. Mai 2024. Vossloh hat erneut den Zuschlag für die Lieferung von Sch...
MasterCraft Boat Holdings, Inc. Reports Results for Fiscal 2024 Third ...
MasterCraft Boat Holdings, Inc. Reports Results for Fiscal 2024 Third Quarter VONORE, Tenn., May 08, 2024 (GLOBE NEWSWIRE) -- MasterCraft Boat Holdings, Inc. (NASDAQ: MCFT) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The overview, commentary, and results provided herein relate to our continuing operations. Overview: Net sales for the third quarter were $95.7 million, down 42.6% from the prior-year periodNet income from continuing operations was $3.8 million, or $0.23 per diluted shareDiluted Adjusted Net Income per share, a non-GAAP measure...
Kornit Digital Reports First Quarter 2024 Results
Kornit Digital Reports First Quarter 2024 Results First quarter revenues of $43.8 million, in line with previous guidanceFirst quarter GAAP net loss of $13.2 million; non-GAAP net loss of $5.3 millionGenerated positive cash flow from operations for the first quarter of 2024Successfully concluded Apollo beta with all three customers and built a healthy pipelineSignificant interest from new and existing customers on the all-inclusive click (“AIC”) model ROSH-HA`AYIN, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- Kornit Digital Ltd. (“Kornit” or the “Company”) (Nasdaq: KRNT), a worldwide market ...
BrainsWay Reports First Quarter 2024 Financial Results and Operational...
BrainsWay Reports First Quarter 2024 Financial Results and Operational Highlights Generated Significant 37% Year-over-Year Revenue Growth in Q1 2024 Recorded Positive Quarterly Net Income for Second Consecutive Quarter, and Positive Adjusted EBITDA and Cash Flow from Operations for Third Consecutive Quarter Conference Call to be Held Today at 8:30 AM ET BURLINGTON, Mass. and JERUSALEM, May 08, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain disorders, today reported first quart...
Kura Oncology to Participate in Bank of America Securities Healthcare ...
Kura Oncology to Participate in Bank of America Securities Healthcare Conference SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2024 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 1:40 p.m. ET / 10:40 a.m. PT on May 15, 2024. A live audio webcast of the fireside chat w...
Verrica Pharmaceuticals to Provide a Corporate Update and Report First...
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 WEST CHESTER, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, May 13, 2024 to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. Individuals ma...
Amerigo Announces Q1-2024 Results & Quarterly Dividend
Amerigo Announces Q1-2024 Results & Quarterly Dividend Q1-2024 net income of $4.3 million Quarterly EBITDA1 of $13.6 million – free cash flow to equity1 of $7.3 million Current copper prices substantially above Q1-2024 average Quarterly dividend of Cdn$0.03 per share declared, representing a 7.7% yield3 VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce financial results for the three months ended March 31, 2024 (“Q1-2024”). Dollar amounts in this news release are in U.S. dol...
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficam...
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that CEDAR-HCM (Clinical Evaluation of Dosing with Aficamten to Reduce Obstruction in a Pediatric Population in HCM), a clinical trial of aficamten in a pediatric population with symptomatic obstructive hypertrophic cardiomyopathy (HCM), is open to enrollment. Aficamten is a next-in-class cardiac myosin inhibitor in ...
Else Nutrition Expands Product Listings at Major U.S. Food Retailer
Else Nutrition Expands Product Listings at Major U.S. Food Retailer Northeast retailer to add Else’s Toddler Omega, Ready-to-Drink Kids Shakes, and 4 flavors of its Super Cereal for Babies across more than 70 stores beginning this June VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- ELSE NUTRITION HOLDINGS INC. () () () ("Else" or the "Company"), is proud to announce that it has expanded its product listings at one of the largest independent food retailers in the United States, which ranks 5th among the largest U.S. supermarkets in terms of sales. Following the successfu...
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-...
Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586 Data Support Advancement to Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024 Full Data from the Phase 1 Study to be Presented at a Medical Congress in 2H 2024 SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced topline data from the Phase 1 study of CK-4021586 (CK-586). The study met its primary and secondary objectives to assess the safety, tolerability and pharmacokinetic...
Kelly to Participate in the 18th Annual Barrington Research Virtual Sp...
Kelly to Participate in the 18th Annual Barrington Research Virtual Spring Investment Conference TROY, Mich., May 08, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: KELYA, KELYB), a leading global specialty talent solutions provider, today announced it will participate in the 18th Annual Barrington Research Virtual Spring Investment Conference on Thursday, May 16, 2024. , president and chief executive officer, , executive vice president and chief financial officer, , president of Kelly Science, Engineering, Technology & Telecom, and Scott Thomas, investor relations, will participate in one-on-one ...
Nexxen to Announce First Quarter 2024 Financial Results on May 20, 202...
Nexxen to Announce First Quarter 2024 Financial Results on May 20, 2024 Conference call and webcast to be held May 20, 2024, at 9:00 AM ET / 2:00 PM BST NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Nexxen International Ltd. (AIM/NASDAQ: NEXN) (“Nexxen” or the “Company”), a global, unified advertising technology platform with deep expertise in video and Connected TV ("CTV"), will release its financial results for the first quarter ended March 31, 2024 before the U.S. market opens on Monday, May 20, 2024. The Company will host a webcast and conference call at 6:00 AM PT / 9:00 AM ET / 2:00...
Genie Energy Announces First Quarter 2024 Results
Genie Energy Announces First Quarter 2024 Results Revenue increased to $119.7 Million and Gross Profit Climbed to $33.8 Million - Both Record First Quarter Levels Income from Operations of $9.8 million, Adjusted EBITDA1 of $11.7 Million and Earnings per Diluted Share of $0.30 Repurchased 250,000 Shares of Class B Common Stock Newark, NJ, May 08, 2024 (GLOBE NEWSWIRE) -- Genie Energy, Ltd. (NYSE: GNE), a leading retail energy and renewable energy solutions provider, today announced results for the first quarter of 2024. Michael Stein, ...
BioRestorative Therapies Enhances Preclinical Metabolic Program with a...
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity — New therapeutic candidate developed using Company’s patented ThermoStem® platform — — Candidate has potential to serve as an adjuvant to existing pharmaceuticals that are FDA approved and marketed towards weight loss — — DMF submission and commencement of first-in-human studies targeted for before the end of 2024 — — Expanding the use of ThermoStem® may open the door to big pharma partnership opportunities — MELVILLE, N.Y., May 08, 2024 (GLOBE NEWSWIRE) -- . ...
InflaRx Reports First Quarter 2024 Financial Results and Provides Busi...
InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update Virtual R&D event to be held on June 5, 2024 from 12:00 to 2:00 PM EDT – highlighting company plans for INF904 and the opportunity, the role of C5aR in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) and C5a/C5aR signaling in human inflammatory diseases INF904 multiple ascending dose (MAD) pharmacokinetic (PK) and pharmacodynamic (PD) data supporting best-in-class potential announced, and plans to initiate Phase IIa in CSU and HS by the end of 2024, with data availability anticipated in 2...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.